Combination of First-in-class NBTXR3, Radiotherapy, and Anti-PD-1 Immunotherapy Demonstrate Efficacy in Treating Resistant Pre-clinical in vivo Models of Lung Cancer

Paris, France; Cambridge, Massachusetts (USA); Apr. 2 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the ‘‘Company’’) a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced preclinical data from studies currently being conducted under its collaborations with The University of Texas MD Anderson Cancer Center and the Weill Cornell [...]